NCT06883448 Implementation of Home Monitoring in Patients With Pulmonary Fibrosis
| NCT ID | NCT06883448 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Pulmonary Fibrosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2024-10-02 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 220 participants in total. It began in 2024-10-02 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to evaluate the impact of structurally replacing half of the outpatient clinic visits for patients with pulmonary fibrosis by home monitoring and video consultations on patient self-management and health(care) outcomes.
Eligibility Criteria
Inclusion Criteria: * A multidisciplinary ILD team diagnosis of pulmonary fibrosis according to ATS/ERS/JRS/ALAT guidelines; * Adults (=/\>18 years). Exclusion Criteria: * Patients who are not able to speak, read and/or write in Dutch; * Patients with no access to the internet; * Patients with a life expectancy of less than 1 year as determined by the treating healthcare provider; * Patients who are or have been using a home monitoring program for PF.
Contact & Investigator
Marlies S. Wijsenbeek-Lourens, Prof Dr
PRINCIPAL INVESTIGATOR
Department of Respiratory Medicine, Center of Excellence for Interstitial Lung Disease, Erasmus University Medical Center, Rotterdam, The Netherlands
Frequently Asked Questions
Who can join the NCT06883448 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Fibrosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06883448 currently recruiting?
Yes, NCT06883448 is actively recruiting participants. Contact the research team at d.hofman@erasmusmc.nl for enrollment information.
Where is the NCT06883448 trial being conducted?
This trial is being conducted at Amsterdam, Netherlands, Arnhem, Netherlands, Breda, Netherlands, Eindhoven, Netherlands and 7 additional locations.
Who is sponsoring the NCT06883448 clinical trial?
NCT06883448 is sponsored by Erasmus Medical Center. The principal investigator is Marlies S. Wijsenbeek-Lourens, Prof Dr at Department of Respiratory Medicine, Center of Excellence for Interstitial Lung Disease, Erasmus University Medical Center, Rotterdam, The Netherlands. The trial plans to enroll 220 participants.